AVCT Avacta Group

Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts

Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts

Encouraging Progression Free Survival (PFS) data observed in patients with salivary gland cancers compared to conventional treatments

LONDON and PHILADELPHIA, March 07, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, is pleased to announce that the lead program of the Company, AVA6000, the first clinical stage asset which is a pre|CISION®-enabled form of doxorubicin, has completed the Phase 1a dose escalation with encouraging PFS data in patients with salivary gland cancers. The Company has initiated enrollment in the Phase 1b expansion cohorts with multiple patients treated.

Promising early efficacy and safety signals are observed in the Phase 1a trial. As of the most recent data cut-off, the favorable safety profile continues to be observed when compared with conventional dose doxorubicin, including no observed events of severe cardiac toxicity, which are associated with conventional doxorubicin.

Among patients in the dose-escalation portion, 11 patients with salivary gland cancers have been treated with AVA6000 at or above the dose of 250 mg/m2 and above. Among these 11 patients, one patient experienced a confirmed partial response as best response (greater than -30% reduction in tumor diameters by RECIST criteria), four patients had minor responses (-10 to -29% reduction by RECIST criteria), and only one patient had disease progression for a disease control rate of 91%. These responses have been durable to date. Importantly, the median PFS has not yet been reached, as five patients remain on AVA6000 treatment and 9 of the 11 patients are without progression and remain in follow-up. The median time of follow-up in this cohort is approximately 5 months. These data compare very favorably to published PFS reports (with conventional anti-cancer therapy) in this setting of pre-treated SGC, is reported at approximately 3.5 months. It is anticipated that PFS would be the primary endpoint in the registrational trial of AVA6000 in this indication, which is characterized by low response rates and high unmet need.

Avacta also announces patient dosing in the AVA6000 Phase 1b expansion cohorts with multiple patients treated in this portion of the trial, which include three indications: (1) salivary gland cancer, (2) triple negative breast cancer and (3) high grade soft tissue sarcoma. Each arm of the Phase 1b expansion cohort will enroll 20-30 patients by the following criteria.

  • Salivary gland cancers: patients with advanced or metastatic salivary gland cancers of any histologic subtype. Patients may have received up to 1 prior line of therapy in the metastatic or advanced setting.

  • Triple negative breast cancer: patients with advanced or metastatic triple negative breast cancer with up to 2 prior lines of therapy in the metastatic or advanced setting.

  • High grade soft tissue sarcomas: patients with undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma and patients may have received 0 or 1 prior line of therapy in the metastatic or advanced setting.

The Company anticipates providing a further update from the Phase 1a dose escalation data in 2Q 2025 and Phase 1b dose expansion cohort data at the end of 2025. The full Phase 1a data will be presented in 2H 2025, including a full assessment of the cardiac safety data with long-term follow up. The data will allow the Company to plan for the registration study of AVA6000.

Alan Ho, MD PhD, Chief of the Head and Neck Oncology Service, Memorial Sloan Kettering Cancer Center and member, Avacta Scientific Advisory Board, commented:

"We are very excited to move the development of AVA6000 to the next level to generate data that demonstrates clinically meaningful efficacy and durability of response in patients with previously treated salivary gland cancers.  It is important to note the high degree of unmet need in this disease where few agents have shown efficacy.  I am happy to participate in the trials of AVA6000 in this disease setting going forward."

Christina Coughlin, CEO of Avacta Therapeutics, commented:

“We are very pleased to advance to the expansion cohorts in the AVA6000 trial in these three indications with high unmet need. Our development of AVA6000 is proceeding according to plans and today’s new data demonstrate the durability of the responses we have observed in the SGC indication. We believe that AVA6000 has an important role to play in the clinic, given our preliminary efficacy data and the large commercial market size of conventional doxorubicin.”

For further information from Avacta, please contact:

Avacta Group plc

Michael Vinegrad, Group Communications

Director
  
Peel Hunt (Nomad and Broker)

James Steel / Chris Golden / Patrick Birkholm



 



Panmure Liberum (Joint Broker)

Emma Earl / Will Goode / Mark Rogers



ICR Healthcare

Mary-Jane Elliott / Jessica Hodgson / Max Bennett
 



 
Investor Contact

Monique Allaire

THRUST Strategic Communications





  



Media Contact

Carly Scaduto

Carly Scaduto Consulting
 

 
  

About Avacta -  

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary payload delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.

About the pre|CISION® Platform

The pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.



EN
07/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Avacta Group

 PRESS RELEASE

Avacta Provides Business Update for the First Quarter of 2025 Outlinin...

Avacta Provides Business Update for the First Quarter of 2025 Outlining Progress Against Strategic Objectives AVA6000 Phase 1b expansion cohorts enrolling with data targeted for later in 2025 AVA6103 IND-enabling studies underway with a Phase 1 trial anticipated to begin in the first quarter of 2026 Multiple presentations at the AACR Annual Meeting highlight the promise of the pre|CISION® platform Transformation into a pure-play therapeutics company prioritizes proprietary pre|CISION® platform and extends cash runway into Q1 2026 LONDON and PHILADELPHIA, March 3...

 PRESS RELEASE

Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meetin...

Avacta Therapeutics Announces Presentations at 2025 AACR Annual Meeting LONDON and PHILADELPHIA, March 26, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the Company will have three presentations at the American Association for Cancer Research (AACR) Annual Meeting from April 25-30, 2025 in Chicago, IL. The poster presentations will feature data from the Company’s proprietary pre|CISION® platform and pipeline of...

Franc Gregori ... (+3)
  • Franc Gregori
  • Lala Gregorek
  • Philippa Gardner

Avacta: Executing steadily on therapeutics focused strategy

Avacta continues its transition into a pure-play therapeutics company to advance its pre|CISION-enabled peptide-drug conjugate platform. The expanding pipeline has the potential to improve the therapeutic index of many highly potent yet systemically toxic oncology drugs. Progress has been tangible with early efficacy and safety data from the Phase Ia salivary gland cancer (SGC) dose escalation cohort of lead asset AVA6000 (FAP-Dox), and confirmation of dosing and ongoing enrolment into Phase Ib ...

 PRESS RELEASE

Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare C...

Avacta Therapeutics to Present at the 2025 Leerink Global Healthcare Conference LONDON and PHILADELPHIA , March 10, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced that the Company will present at the Leerink Global Healthcare Conference on Wednesday, March 12, 2025, at 10:00 a.m. ET in Miami. A live webcast of the presentation will be available in the investors section of the Company’s website at /investors. The webcas...

 PRESS RELEASE

Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 ...

Avacta Announces Promising Early Efficacy and Safety Data for AVA6000 in the Phase 1a Dose Escalation and Ongoing Enrollment in the Phase 1b Expansion Cohorts Encouraging Progression Free Survival (PFS) data observed in patients with salivary gland cancers compared to conventional treatments LONDON and PHILADELPHIA, March 07, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, is pleased to announce that the lead program of the Company, AVA...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch